Viewing Study NCT01019395


Ignite Creation Date: 2025-12-24 @ 1:18 PM
Ignite Modification Date: 2025-12-27 @ 6:36 AM
Study NCT ID: NCT01019395
Status: COMPLETED
Last Update Posted: 2019-11-13
First Post: 2009-11-23
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Pharmacokinetics (PK) and Safety Evaluation of Daptomycin in Children Ages 3-24 Months With Proven or Suspected Gram-positive Infections or Peri-Operative Subjects Receiving Prophylactic Antibiotics
Sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module